Status:
TERMINATED
The Effects of Enoximone in Acute Exacerbation COPD
Lead Sponsor:
Rijnstate Hospital
Conditions:
COPD Exacerbation
Enoximone
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Introduction: The pharmacodynamic properties of enoximone could be beneficial for patients with an Acute Exacerbation COPD (AE-COPD). This research will focus on patients suffering of a severe AE-COP...
Detailed Description
Ventilator will be set during the study period at Volume Controle, 6 ml/kg, 5 PEEP and a respiratory rate of 15 bpm with an I:E-ratio of 1:2. Salbutamol/ipratropium bromide and magnesium sulphate wil...
Eligibility Criteria
Inclusion
- Patients with an AE-COPD for which intubation occurred within 24 hours before enrolment.
Exclusion
- Patients with known asthma or interstitial lung disease (ILD)
- Known neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Guillain-Barre and Dementia
- Hypertrophic obstructive cardiomyopathy (HOCM)
- Severe aortic stenosis with aortic valve area \< 1cm2
- Known ventricular arrhythmias
- Severe kidney disorders with Glomerular Filtration Rate (GFR) \< 30
- Severe liver insufficiency with spontaneous PT/INR \> 1.5
- Pregnancy
- Lactation
- High dose-diuretics use (daily dose of \>480 mg furosemide)
Key Trial Info
Start Date :
May 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 21 2021
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04420455
Start Date
May 12 2020
End Date
December 21 2021
Last Update
January 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M.V. Koning
Arnhem, M, Netherlands